Covaxin – India’s Covid-19 Vaccine.

covaxin India's covid 19 vaccine.

covaxin indias covid 19 vaccine. India recorded another spike in the cases of the coronavirus disease (Covid-19) The Union health ministry’s data showed Maharashtra, India’s worst-hit state has 192,990 Covid-19 cases and 8,376 fatalities so far. The number of coronavirus cases has exceeded 11 million and killed more than half a million people since December last year when china first reported.

IndiaLast Updated: Loading...
Total Cases0
New Cases0
Total Deaths0
New Deaths0
Total Recovered0
Active Cases0
Critical0
Case/1M0
Deaths/1M0
Total Tests0
Tests/1M0

When the Covid-19 vaccine will be launch?

The first made-in-India coronavirus vaccine may launch by August 15. “BBV152 COVID vaccine” is the name of COVID-19 vaccine.  Indian Council of Medical Research (ICMR) is putting its all efforts to develop ” Covaxin ” in partnership with Bharat Biotech International Limited.

where the coronavirus vaccine is developing?

Hyderabad-based, Bharat Biotech India Ltd (BBIL) developed covaxin. They got approvals from the drug controller general of India on June 29 for first and second phase trial. Some Institutes are there for clinical trials of the COVID-19 vaccine.

How they make Covid-19 vaccine?

covaxin indias covid 19 vaccine. “The vaccine is derived from a strain of SARS-CoV-2(severe acute respiratory syndrome coronavirus 2) Isolated by Indian Council of Medical Research-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the pre-clinical as well as clinical development of this vaccine,” the ICMR said in a letter to the institutes.

How they are testing the covid-19 vaccine?

Animal trial is done by the company and collected data is submitted to DCGI (Drug Controller General of India), Animals like- mice, rabbits, guinea pigs, rats were used and as per agency report the good news is – these animals developed antibodies against the virus .

ICMR asked institutes to step up clinical trials as it is a High priority project watched at the topmost level of the government. The trials are done on groups of people and meant to test if the vaccine is safe in humans and produces protective antibodies. The potential vaccine in question is a SARS-COV-2 strain sourced from the ICMR-National Institute of Virology. The aim is to test if the weakened form of the virus can stimulate enough immunity to protect healthy people from SARS COV-2 infection.

On July 2, Director General of the Indian Council of Medical Research (ICMR) Dr. Balram Bhargava sent out a letter and they ask officials at 12 hospitals across the country to speed up the vaccine testing process.

How many vaccines are there till now?

Interestingly, pharmaceutical big, Cadila attention has been within the news for ramping up its analysis on not one however two coronavirus vaccine candidates still because the production of Plaquenil ,or HCQ drug to fight COVID-19.

A immunogen candidate by Asian country Biotech received approval to enter initial phases of human clinical trials solely earlier on. in a very letter to Asian country Biotech and chosen hospitals for trials, ICMR director general Balram Bhargava suggested “to fast-track all approvals associated with initiation of the clinical test and make sure that the topic incoming is initiated no later than Gregorian calendar month 7” seeable of the general public health emergency and “urgency to launch the vaccine”.

Results of covid-19 vaccine test.

A report mentioned that Ahmedabad based Zydus Cadila saw satisfactory results in the pre-clinical trials and various animal studies, post which, the regulatory board issued them the go-ahead to start the trials.

IS it okay to do covid-19 vaccine trials on human?

However, a paragraph in Dr. Bhargava’s letter suggested a haste and presumption of the vaccine’s protective abilities.

BBIL is working expeditiously to meet the target However, outcome will depend on the cooperation of all clinical trial sites involved in this project.”

Indian Mobile Companies

PARSH:

This website uses cookies.